Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma

RecruitingOBSERVATIONAL
Enrollment

1,600

Participants

Timeline

Start Date

July 17, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Hepatocellular Carcinoma
Trial Locations (1)

10002

RECRUITING

National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

Chi Mei Medical Hospital

OTHER

collaborator

National Taiwan University Hospital Hsin-Chu Branch

OTHER

collaborator

National Taiwan University

OTHER

collaborator

Taichung Veterans General Hospital

OTHER

collaborator

E-DA Hospital

OTHER

collaborator

Chiayi Christian Hospital

OTHER

collaborator

Srinagarind Hospital, Khon Kaen University

OTHER

lead

National Taiwan University Hospital

OTHER

NCT07091942 - Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter